Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Volpara (ASX:VHT) share price falls despite excellent FY24 Q1

The Volpara Health Technologies Ltd (ASX:VHT) share price is down 4% after reporting its FY24 first quarter, which was strong.

The Volpara Health Technologies Ltd (ASX: VHT) share price is down 4% after reporting its FY24 first quarter, which was strong.

Volpara FY24 first quarter

The ASX healthcare share reported cash receipts of NZ$11 million, which was up 27% (or 21% if the same foreign exchange rate was used).

It said that it made the third straight positive quarter of net operating cash flow, with an improvement of 100% from last year’s net outflows of NZ$2.8 million, to NZ$9,000 in this quarter.

The company has been operating cash flow positive since September 2022, to the tune of around NZ$2.4 million.

The ASX healthcare share said that it’s heading towards being net operating cash flow positive in FY24, which is a full year ahead of guidance. That’s great news for the long term for the Volpara share price.

Volpara’s software as a service (SaaS) statistics were good. The contracted annual recurring revenue (CARR) is now around US$27.2 million, or approximately US$44.1 million. This was an increase of US$700,000 on the prior quarter (the fourth quarter of FY23).

The company’s annual recurring revenue (ARR) is now US$21.5 million, or approximately NZ$34.9 million, up from US$20.9 million in the last quarter.

Management commentary

The Volpara CEO and Managing Director Teri Thomas said:

It’s been a great quarter, with our recognition as Microsoft’s global Healthcare and Life Sciences Partner of the Year, but most importantly the continued growth of our customer base. What matters most is the positive impact on families, and our growth and financial strength allow us to explore ways to expand that impact. We are energised and growing both in the United States and in Australia, with the addition of Breast Screen Victoria. We could not be more pleased.

Final thoughts on the Volpara share price

Volpara continues to do extremely well at growing revenue, increasing its future revenue (with ARR growth), make positive cash flow and strengthen its position in the market.

It’s not as cheap as it was a month ago – having risen by around 25% in the last month – but I still think it’s got a very exciting future considering revenue keeps growing at a double digit rate and it has a gross profit margin of over 90%.

I’d call this one of the most exciting ASX growth shares around, and a long-term buy.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content